medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Graphical Abstract

Improving Clinical Decision-Making in Radiotherapy: A Comparative Analysis of LQ and LQL Dose Models

Cyril Voyant, Daniel Julian, Stéphane Muraro, Véronique Bodez, Morgane Pinpin, Delphine Leschi, Rashid Oozeer, Wided Guiddi, Marie-Aimée Acquaviva, Severine Prapant, Omar Gahbiche, Noureddine Bouaouina

Workflow of Advanced Dose Modeling in Radiotherapy



NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Highlights

Improving Clinical Decision-Making in Radiotherapy: A Comparative Analysis of LQ and LQL Dose Models

Cyril Voyant, Daniel Julian, Stéphane Muraro, Véronique Bodez, Morgane Pinpin, Delphine Leschi, Rashid Oozeer, Wided Guiddi, Marie-Aimée Acquaviva, Severine Prapant, Omar Gahbiche, Noureddine Bouaouina

- ✓ Advanced dose modeling using LQ and LQL frameworks for precise radiotherapy planning.
- ✓ Accurate computation of BED and NTCP to optimize tumor control and minimize toxicity.
- ✓ Patient-specific optimization integrating fractionation schedules and OAR constraints.
- ✓ Clinical validation through case studies, revealing variability in treatment planning decisions.
- ✓ Call for standardized guidelines and training to bridge the gap between theory and practice.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Improving Clinical Decision-Making in Radiotherapy: A Comparative Analysis of LQ and LQL Dose Models

Cyril Voyant[a,*], Daniel Julian[b], Stéphane Muraro[b], Véronique Bodez[c], Morgane Pinpin[d], Delphine Leschi[d], Rashid Oozeer[d], Wided Guiddi[e], Marie-Aimée Acquaviva[d], Severine Prapant[d], Omar Gahbiche[e], Noureddine Bouaouina[e]

[a] *Mines Paris, PSL University, Centre for observation, impacts, energy (O.I.E.), Sophia-Antipolis, 06904, Antibes, France*
[b] *Centre de Cancérologie du Grand Montpellier, Radiotherapy Unit, Montpellier, 34000, Hérault, France*
[c] *Sainte Catherine, Institut du Cancer, Medical Physics Department, Avignon, 84000, Provence, France*
[d] *CH Castelluccio, Radiation Unit, Ajaccio, 20000, Corsica, France*
[e] *Centre Médical IBN Khaldoun, Radiotherapy Unit, Hammam Sousse, 4011, Tunisie*

Abstract

Radiotherapy is an essential component of cancer treatment, requiring accurate dose planning to optimize tumor control while sparing healthy tissues. This study investigates advanced dose modeling approaches, focusing on the Linear Quadratic (LQ) and Linear Quadratic Linear (LQL) models, to refine the calculation of biologically effective doses (BED) and improve treatment personalization. Using tools such as LQL-equiv and other BED calculators, we integrated patient-specific data (e.g., fractionation schedules and organ-at-risk (OAR) constraints) to predict outcomes such as normal tissue complication probabilities (NTCP). Through a series of clinical case studies (including treatment interruptions, palliative boosts, and reirradiation scenarios), participant responses were analyzed using the Jaccard similarity index, revealing a significant lack of consensus in treatment planning decisions (mean agreement of 10%). This variability highlights a critical gap between the potential of advanced modeling and its consistent clinical application. While the LQ and LQL models offer promising tools for personalized radiotherapy, their interpretation and implementation remain highly variable. This study emphasizes the need for standardized guidelines, enhanced training programs, and decision-support systems to reduce inter-observer variability and ensure effective clinical adoption, ultimately improving patient care.

Keywords: Radiotherapy, Biologically Effective Dose (BED), Linear Quadratic Model (LQ), Dose Optimization, Personalized Cancer Treatment

1. Introduction

Modern advancements in radiotherapy and dose modeling stem from foundational developments in radiobiology. This study, originating from a workshop on advanced radiotherapy modeling, revisits key milestones to highlight the tools and concepts that have shaped contemporary clinical approaches. The workshop brought together experts in the field to discuss and evaluate the latest advancements, providing a comprehensive overview of current best practices and emerging trends.

1.1. Historical Background in Radiobiology

Radiotherapy has evolved significantly since Lea and Catcheside's work on indirect radiation effects [7]. The Linear Quadratic (LQ) model, pivotal in the 1980s, facilitated fractionation modeling [12] and became a cornerstone for dose calculation due to its simplicity and broad applicability. However, its limitations at high doses, such as overestimating cell survival, led to the development of refined models. Lyman's dose-volume histograms improved the prediction of tissue complications [8], providing a more accurate assessment

*Corresponding author

Email addresses: cyril.voyant@minesparis.psl.eu (Cyril Voyant), Julian@ccgm.fr (Daniel Julian), muraro@ccgm.fr (Stéphane Muraro), v.bodez@isc84.org (Véronique Bodez), morgane.pinpin@ch-castelluccio.fr (Morgane Pinpin), delphine.leschi@ch-castelluccio.fr (Delphine Leschi), rashid.oozeer@ch-castelluccio.fr (Rashid Oozeer), guiddiwided@yahoo.fr (Wided Guiddi), marie_aimee2a@hotmail.com (Marie-Aimée Acquaviva), severine.prapant@ch-castelluccio.fr (Severine Prapant), omargahbiche.cmik@gmail.com (Omar Gahbiche), noureddine.bouaouina3@gmail.com (Noureddine Bouaouina)

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 1: Responsibilities and Workflow in Radiotherapy Dose Calculation, with References to French and European Legal Texts. This diagram outlines the roles of key stakeholders in ensuring safety, accuracy, and regulatory compliance during dose prescription and calculation, referencing legal frameworks such as EU Regulation 2017/745 and French decrees like R. 4127-8 and R. 4351-1.

Table 1: Responsibilities in Case Studies of Software Defects and Misuse in Radiotherapy

Case Study	**Defective Software: Patient dies or suffers irreversible harm due to a software defect causing incorrect dose calculations.**	**Misuse of Software: Patient dies or suffers irreversible harm due to a user error in dose calculation.**
Primary Responsibility	Developer: Responsible for testing and safety compliance (e.g., *EU Reg. 2017/745*). Negligence liability if a defect caused harm.	Physicist/Oncologist: Responsible for accurate data entry and following protocols. Liability if misuse caused harm.
Secondary Responsibility	IT Department: Accountable if risk monitoring was insufficient to catch defects.	Healthcare Facility Director: Responsible if training or guidance was inadequate. Liability for insufficient protocols or oversight.
Shared/Indirect Responsibility	Facility Director: Liable if the software was uncertified or improperly vetted for clinical use.	Developer: Some responsibility if unclear interface contributed to error. Must ensure software is intuitive and provides clear instructions.
Legal Implications	- Negligence for the developer or IT if defect was undetected. - Regulatory breach if uncertified software was used, per EU standards.	- Malpractice liability for the healthcare professional if error stemmed from user negligence. - Institutional liability if misuse was due to inadequate training.

of the risk to healthy tissues. Fowler's Biologically Effective Dose (`BED`) standardized dose equivalence across different fractionation schemes [5], making it easier to compare different treatment protocols. Dale further enhanced the model by incorporating tumor repopulation effects [3], which are crucial for accurately predicting treatment outcomes. To address the high-dose limitations of the `LQ` model, Astrahan proposed the Linear Quadratic Linear (`LQL`) model [1], which better accounts for cell survival at higher doses. This model is particularly useful in scenarios involving high-dose treatments, such as stereotactic radiosurgery. Niemierko's introduction of the Equivalent Uniform Dose (`EUD`) provided a framework for handling dose inhomogeneities [9], allowing for more precise treatment planning. Recent advancements have integrated Relative Biological Effectiveness (`RBE`), particularly for ion and proton therapies, further refining dose calculation accuracy [4, 10]. These models consider the varying biological effects of different types of radiation, improving the precision of dose calculations. Despite these advancements, the clinical application of these models remains inconsistent. This study aims to evaluate the `LQ` and `LQL` frameworks in the context of modern radiotherapy, highlighting their strengths, limitations, and potential for standardization.

1.2. Legislation and Responsibility

Modern radiotherapy is governed by stringent guidelines to ensure safety and efficacy. Regulatory frameworks, such as EU Regulation 2017/745 and French decrees (e.g., R. 4127-8 and R. 4351-1), mandate accurate dose calculation and strict adherence to organ-at-risk (`OAR`) constraints. These regulations require continuous monitoring of patient outcomes and adaptive strategies to address treatment interruptions, evolving patient conditions, and technological advancements. Practitioners must balance clinical responsibilities with legal requirements, as outlined in international safety standards [6]. For a detailed overview of the roles and responsibilities of key stakeholders, see Figure 1 and Table 1. To minimize risks associated with software defects or misuse, healthcare facilities should implement robust quality assurance programs. These programs should include regular software audits, comprehensive training for staff, and clear protocols for dose calculation and verification. Such measures not only ensure compliance with legal standards but also enhance patient safety and treatment efficacy.

1.3. The Importance of `BED` *and* `NTCP`

The Biologically Effective Dose (`BED`) has become a key element for quantifying the biological impact of different fractionation schemes, enabling direct comparison of diverse protocols [2]. By accounting for dose per fraction, total dose, and tissue-specific parameters, `BED` provides a unified metric to evaluate and

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

optimize treatment plans. For example, it allows clinicians to compare conventional fractionation (e.g., 2 Gy per fraction) with hypofractionated regimens (e.g., 5 Gy per fraction) while maintaining equivalent biological effectiveness. Similarly, the Normal Tissue Complication Probability (NTCP) metric facilitates risk estimation for organ damage, guiding personalized treatment planning. NTCP models integrate dose-volume histograms and radiobiological parameters to predict the likelihood of complications, such as radiation-induced pneumonitis or fibrosis. However, their accuracy depends on the quality of the underlying data and the applicability of the model to specific patient populations. Together, BED and NTCP offer a robust framework to optimize treatment outcomes and manage toxicity. Despite their widespread use, challenges remain, including inter-patient variability and the need for standardized implementation across clinical centers. This study aims to address these challenges by evaluating the consistency and applicability of these metrics in concrete scenarios.

1.4. Objectives

This study, originating from a workshop on advanced radiotherapy modeling, investigates the integration of sophisticated dose models, particularly the Linear Quadratic (LQ) and Linear Quadratic Linear (LQL) frameworks, in radiotherapy planning. One of its key aims is to validate the applicability of Biologically Effective Dose (BED) and Normal Tissue Complication Probability (NTCP) metrics across diverse clinical scenarios. Additionally, it evaluates the consistency of participant responses by employing the Jaccard similarity index [11], revealing potential variability in treatment planning decisions. The study also examines the practical implementation of LQ and LQL models through a series of case studies, including treatment interruptions and reirradiation cases, to assess their real-world relevance. Finally, it advocates for the development of standardized guidelines to facilitate the adoption of advanced dose modeling, aiming to minimize inter-observer variability and enhance clinical decision-making. By addressing these aspects, the study seeks to bridge the gap between theoretical radiobiological models and their practical application, ultimately contributing to improved radiotherapy safety and efficacy.

2. Methods

LQL-equiv is an open-source tool for dose-equivalence modeling. Built on the Linear Quadratic Linear (LQL) framework, LQL-equiv addresses the limitations of traditional LQ models, particularly for extreme fractionations. The tool was selected for this study due to its integration of advanced radiobiological models (LQ, LQL, and BED), its adoption in over 20 countries, and its ability to comprehensively simulate complex clinical scenarios. While LQL-equiv is a research-oriented tool without clinical certification (a common limitation among dose calculation software), it provides critical insights into dose optimization and model limitations, helping practitioners calibrate and validate clinical protocols used in their respective centers.

2.1. Workflow of LQL-equiv

Figure 2 outlines the workflow of $\mathtt{LQL-equiv}$. Data acquisition consists of inputting patient-specific data, including total dose, dose per fraction, pause days, and fractionation schedule. The Linear-Quadratic Linear (LQL) model is then applied to compute the Biologically Effective Dose (BED):

$$\mathtt{BED} = n \times d \left(1 + \frac{d}{\alpha/\beta}\right) + \lambda(d - d_t) \tag{1}$$

where n is the number of fractions, d is the dose per fraction, α/β is the tissue-specific parameter, λ accounts for treatment breaks, and d_t is the threshold dose. For the target volume (TV), tumor repopulation effects are considered:

$$\mathtt{BED}_{TV} = n \times d \left(1 + \frac{d}{\alpha/\beta}\right) - \frac{\ln(2)}{\alpha}\frac{T - T_k}{T_{pot}} \tag{2}$$

where T_k represents the kick-off time for tumor repopulation, T_{pot} is the potential doubling time, and T is the total treatment duration. For the organ at risk (OAR), the BED calculation accounts for repair capacity and dose constraints:

$$\mathtt{BED}_{OAR} = n \times d \left(1 + (1 + H_m)\frac{d}{\alpha/\beta}\right) - D_{rec} \times T \tag{3}$$

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2: Methodology of `LQL-equiv`: From data acquisition to dose validation. This workflow includes the radiobiological equations and calculations underpinning the software.

where H_m represents the repair factor, D_{rec} is the recommended maximum dose, and T is the treatment duration. To enable comparisons across fractionation schemes, the Equivalent Dose in 2 Gy Fractions (`Eq2Gy`) is computed as:

$$\texttt{Eq2Gy} = D \times \frac{d + \alpha/\beta}{2 + \alpha/\beta} \tag{4}$$

Optimization is performed to adjust treatment parameters and minimize the difference between the calculated `BED` and the reference `BED`:

$$\arg\min_{n,d,T_k} |\texttt{BED}_{TV} - \texttt{BED}_{ref}|, \quad \arg\min_{\substack{n,d,\\ H_m,D_{rec}}} |\texttt{BED}_{OAR} - \texttt{BED}_{ref}| \tag{5}$$

For bi-fractionated treatments involving two daily dose fractions, the total `BED` is computed as:

$$\texttt{BED}_1 = d_1 \times \left(1 + \frac{d_1}{\alpha/\beta}\right) \tag{6}$$

$$\texttt{BED}_2 = d_2 \times \left(1 + \frac{d_2}{\alpha/\beta}\right) \tag{7}$$

$$\texttt{BED}_{total} = \texttt{BED}_1 + \texttt{BED}_2 - \text{repopulation correction factor} \tag{8}$$

Finally, the workflow generates optimized treatment plans, including dose adjustments and `NTCP` estimates. This framework integrates tumor-specific and `OAR` constraints into `BED` and `Eq2Gy` calculations, optimizing treatment personalization and minimizing complications. The use of repopulation correction and fractionation adjustments allows for precise radiotherapy planning.

2.2. Participant Evaluation and Metrics

Participants in this study were attendees of the *27th Congrès National de Cancérologie et de Radiothérapie-2024*, held in Sousse, Tunisia, on November 22–23, 2024. This event gathered over 1,000 registrants, with approximately 20% attending in person and the rest participating virtually. The diversity of attendees, including radiation oncologists, medical physicists, and radiotherapy technicians, enhanced the analysis by incorporating a broad range of perspectives and expertise. During the workshop, participants were divided

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

into heterogeneous groups of five, each comprising a mix of physicians, physicists, and technicians. This structure was designed to foster interdisciplinary collaboration and encourage knowledge sharing, promoting a deeper understanding of the challenges and solutions in radiotherapy dose optimization. Each problem (four in total) was first introduced by the facilitators (C. Voyant and D. Julian), providing the necessary context and theoretical background. Groups were then given time to discuss and respond to each case using a provided paper-based booklet. At the end of the session, each participant submitted their own completed booklet, ensuring an individual record of their approach to each clinical scenario. These booklets were then collected for analysis, allowing for an evaluation of the similarities and discrepancies between responses across all cases. Each group had access to a dedicated computer equipped with `LQL-equiv` and other dose calculation tools[1]. These tools were selected to provide a comprehensive comparison of different dose calculation methodologies, enabling participants to explore their respective strengths and limitations. Participants alternated in using the software, fostering a dynamic and interactive approach to problem-solving. Discussions within the groups allowed for collaborative decision-making and real-time exploration of complex cases. This interactive format ensured that all participants, regardless of their background, could contribute to the decision-making process. Furthermore, the collaborative environment facilitated the exchange of best practices and reinforced the importance of interdisciplinary teamwork in optimizing radiotherapy treatments.

2.3. Data Collection and Analysis

The clinical cases used in this study were pre-defined to evaluate participant decision-making in scenarios such as treatment interruptions, palliative boosts, and reirradiation (details in Appendix A). Each case included specific dosimetric constraints (e.g., maximum spinal cord dose, mean cardiac dose) and required participants to propose adjusted treatment plans. Responses were collected via a homemade survey platform (using MATLAB), ensuring independent and anonymized participation. The Jaccard similarity index was used to quantify agreement among participants, with additional summary statistics (e.g., response rates, most frequent adjustments) providing further insights into decision-making patterns. While there are many mathematical tools available to perform this operation, we aimed to keep it very simple and as objective as possible, knowing that the goal was solely to check if the responses (to one decimal place) were homogeneous or not. The global response rate for all answers (3 per clinical case as described in Appendix A) is close to 70%. This suggests that some participants either did not have enough time or were unsure of the method to use. For further details on `LQL-equiv`, including download links and technical documentation, visit:

- ✓ `https://github.com/cyrilvoyant/LQ-Equiv`
- ✓ `https://cloud.minesparis.psl.eu/index.php/s/dzoXsjaD9MCc5aw/download`

For additional information, see Voyant et al. [14, 13].

3. Results

The analysis of participant responses demonstrated diverse strategies for addressing clinical challenges, reflecting the variability in decision-making even among experienced practitioners. To illustrate these findings, we present detailed case studies, beginning with an interrupted treatment scenario. These examples highlight participant reasoning and adjustments, revealing common trends and deviations. Full details of the clinical scenario and associated question are provided in Appendix A. For reference, a sample solution calculated by the authors using `LQL-Equiv` is also included.

3.1. Case Study 1: Treatment Interruption in Curative Radiotherapy

This case involved a patient undergoing curative radiotherapy who experienced a one-week treatment interruption due to radiation-induced skin toxicity. The interruption occurred after two weeks of treatment, with 10 fractions already delivered. Participants were tasked with determining the optimal therapeutic plan to resume treatment while adhering to strict dosimetric constraints. The clinical and dosimetric challenge required maintaining the original number of planned fractions while ensuring the safety of critical organs-at-risk (`OAR`). Specific criteria included:

[1] `https://www.mdapp.co/biologically-effective-dose-bed-calculator-493/`, `https://www.mdcalc.com/calc/10111/radiation-biologically-effective-dose-bed-calculator`, and `https://www.sfjro.fr/ilq/fr/ilq.html?checkbox=1`

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

- ✓ Maximum spinal cord dose (`PRV`): 46 Gy.
- ✓ Mean cardiac dose (`EUD`): Below 7 Gy.
- ✓ Maximum bowel dose (`V50`): Under 10%.

Participants evaluated potential acute and late treatment effects, ensuring that the Normal Tissue Complication Probability (`NTCP`) remained below 5%. This scenario required individualized dose adjustments for three anatomical regions: head and neck (`ORL`), breast, and bladder. Adjustments to the prescribed fraction doses were recorded to ensure compliance with clinical and dosimetric constraints for each region. The analysis revealed significant variability in participant responses, with proposed fraction doses ranging from 1.8 Gy to 2.5 Gy for the head and neck region, 2.0 Gy to 2.4 Gy for the breast, and 1.9 Gy to 2.3 Gy for the bladder. This variability underscores the challenges of standardizing dose adjustments in complex clinical scenarios, even when using advanced tools like `LQL-Equiv`. The most frequent adjustments (mode) were 2.2 Gy for the head and neck, 2.1 Gy for the breast, and 2.1 Gy for the bladder, indicating a tendency toward moderate dose escalation to compensate for the interruption.

3.2. Case Study 2: Palliative Boost for Cerebellar Metastasis

This case involved a patient with a symptomatic cerebellar metastasis from breast cancer, undergoing palliative radiotherapy. The standard protocol comprised whole-brain irradiation delivering 30 Gy in 10 fractions. Due to severe symptoms, a targeted dose escalation was required for the cerebellar lesion to improve local tumor control and symptom relief while adhering to strict dosimetric constraints. The clinical objectives were:

- ✓ Deliver at least 45 Gy (`Eq2Gy`) to the metastasis.
- ✓ Limit the maximum brain dose to 50 Gy (`Eq2Gy`).
- ✓ Protect vision-related `OAR`, keeping doses below 45 Gy (`Eq2Gy`).

Participants evaluated two therapeutic approaches, Sequential Boost (administered after whole-brain irradiation, requiring specification of the number of fractions and dose per fraction) and simultaneous Integrated Boost (`SIB`; integrated into whole-brain treatment, requiring only the dose per fraction to be recorded). They were tasked with selecting one of the approaches and providing a global decision. For both strategies, adherence to clinical objectives and prioritization of shorter treatment schedules, where feasible, were emphasized.

3.3. Case Study 3: Treatment Interruption and Resumption

This case involved a metastatic lung cancer patient undergoing radiotherapy targeting the L2-L3 vertebrae. The initial treatment plan prescribed 30 Gy over 10 fractions. After completing 5 fractions, a two-week interruption occurred due to hospitalization. Participants were tasked with proposing a therapeutic plan to resume treatment while maintaining the same biological effectiveness as initially planned. Two resumption strategies were considered:

- ✓ Maintaining the remaining 5 fractions.
- ✓ Modifying the number of remaining fractions.

In both strategies, participants had to ensure that the maximum spinal cord dose remained below 34 Gy (physical dose). For each approach, participants calculated the equivalent biological dose for various fractionation schemes and proposed an updated plan aligned with these constraints. The clinical challenge involved recalculating fractionation to achieve the original therapeutic objectives. For each strategy, the dose per fraction was specified, and participants provided a global decision on whether to maintain or modify the number of fractions.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2: Summary of Participant Responses Across Clinical Cases. Key observations are based on an analysis of participant responses, rather than direct feedback

Clinical Cases	Consensus (J Index)	Most Frequent Response (Mode)	Key Observations
Case 1	ORL : 10% Breast : 15% Bladder : 15%	2.2 Gy 2.1 Gy 2.1 Gy	Significant dose divergence. Balance between local control and toxicity is crucial.
Case 2	Sequential : 30% SIB : 22% Choice : 60%	2 fractions-3Gy 3.5 Gy SIB	Preference for SIB despite moderate overall consensus. Treatment planning choice is key.
Case 3	same # fractions : 17% Different # fractions : 26% Choice : 60%	3.5 Gy 4.5 Gy 5 fractions	High heterogeneity in practice. Fraction number and dose vary depending on approach.
Case 4	5 fractions : 20% 6 fractions : 15% 7 fractions : 20%	4.2 Gy 3.5 Gy 3.2 Gy	Lack of clear consensus. Wide range of fractionation schedules considered.

3.4. Case Study 4: Spinal Cord Dose Limitation in Reirradiation

This scenario involved a patient previously treated 10 years ago for breast cancer, receiving a maximum dose of 23 Gy to the spinal cord over 23 fractions (26 Gy to the planning risk volume, PRV, of the spinal cord +5 mm) on a volume of 0.03 cc. The patient now requires reirradiation targeting the T3 vertebral body with a proposed prescription of 5 fractions of 7 Gy each. The clinical challenge was to limit spinal cord toxicity while ensuring effective tumor control. Participants calculated dose equivalence using the 2 Gy equivalent dose (Eq2Gy) or Biologically Effective Dose (BED) models, accounting for accumulated doses from prior treatments. Constraints from the International Spine Radiosurgery Consortium Guidelines were strictly applied:

- ✓ Maximum dose (Dmax) to the spinal cord: < 28 Gy (0.03 cc).
- ✓ Volume receiving > 22 Gy (V22Gy): < 0.35 cc.

Participants were encouraged to use LQ or LQL frameworks to evaluate fractionation schemes and ensure compliance with dose constraints. They determined the dose per fraction for spinal cord protection under three fractionation schemes (5, 6, or 7 fractions). Each option required specifying the dose per fraction to balance therapeutic effectiveness and spinal cord safety.

3.5. Discussion

The findings of this study highlight the potential of advanced dose modeling in radiotherapy treatment planning. However, the analysis of participant responses to clinical case studies revealed significant variability in the proposed solutions. As shown in Table 2, the Jaccard similarity index (J) indicated a mean agreement of only 25.83% among participants. This low concordance highlights several crucial points. Firstly, it reveals that even when using dose-equivalence calculation tools such as LQL-equiv and other available BED calculators, practitioners arrive at divergent therapeutic conclusions. This divergence persists even when participants use the same tool, suggesting that the interpretation of results and their clinical application vary considerably. The observed differences are sometimes disconcerting, underscoring the inherent complexity in applying radiobiological models in real clinical contexts. Analysis of Table 2 allows us to further specify this observation:

- ✓ Case 1 (Treatment Interruption): The low concordance (10% for ORL, 15% for Breast and Bladder) associated with similar proposed doses (2.1 Gy and 2.2 Gy) indicates uncertainty regarding the optimal strategy for compensating for the interruption. Although the doses are numerically close, the biological impact of this slight difference, particularly in terms of BED, could be significant. This suggests that even small variations in fraction doses can generate debate regarding the benefit/risk balance.
- ✓ Case 2 (Palliative Boost for Cerebellar Metastasis): A marked preference (60% of choices) for the use of SIB is observed, despite moderate consensus on specific parameters (30% for sequential fractionation and 22% for SIB). This preference for SIB could reflect a desire for treatment simplification or a perception of better clinical efficacy, although the data do not allow us to confirm this.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

- ✓ Case 3 (Treatment Interruption and Resumption): This case presents high heterogeneity in practice, with a distribution of choices between maintaining the number of fractions (17%) and modifying it (26%), and an overall preference for 5 fractions (60% of choices). The associated doses (3.5 Gy and 4.5 Gy) also demonstrate significant variability. This heterogeneity underscores the difficulty of establishing a standardized protocol for managing treatment interruptions and the need for an individualized approach.

- ✓ Case 4 (Spinal Cord Dose Limitation in Re-irradiation): The lack of clear consensus (20% for 5 and 7 fractions, 15% for 6 fractions) and the dispersion of proposed doses (between 3.2 Gy and 4.2 Gy) reflect the complexity of re-irradiation, particularly due to strict dose constraints on the spinal cord. Calculating `Eq2Gy` or `BED` in this context is crucial, but the results show that even with these tools, interpretation and clinical decisions diverge.

Several factors can explain this variability. One key issue is the heterogeneous training received by practitioners regarding the use and limitations of `LQ` and `LQL` models. While these models are well documented in the literature, their translation into clinical routine remains inconsistent. Additionally, the lack of standard guidelines on their application in specific scenarios, such as treatment interruptions or reirradiation, forces clinicians to rely on individual experience rather than established protocols. Furthermore, although digital tools such as `LQL-equiv` provide objective calculations, their interpretation remains subjective, particularly in complex cases where multiple fractionation strategies are feasible. The clinical impact of this variability is not trivial. A difference of 0.2 to 0.5 Gy per fraction, though seemingly small, can significantly alter the total biological dose (`BED`) received by the tumor and organs at risk. In the context of reirradiation, such discrepancies can lead to suboptimal tumor control if the dose is underestimated, or to severe complications if it is overestimated. This highlights an urgent need for standardized reference values and decision-support tools that can guide clinicians towards more consistent and reproducible treatment planning.

4. Conclusion

This study explored the integration of advanced dose modeling, specifically the `LQ` and `LQL` models, into clinical radiotherapy planning. The analysis of participant responses across diverse case studies revealed a concerning lack of agreement in treatment planning decisions, despite the availability of tools like `LQL-equiv` and other `BED` calculators. This underscores that while advanced modeling offers the potential for personalized and optimized treatments, the interpretation of model outputs and their translation into clinical practice remain highly variable. Therefore, successful integration of these models requires a strong emphasis on standardization. We recommend the development of comprehensive guidelines, standardized training programs focusing on both theoretical understanding and practical application, and exploration of AI-based decision support systems to minimize inter-observer variability and ensure consistent, effective clinical adoption of advanced dose modeling in radiotherapy. In addition, this paper presents clinical cases frequently encountered in radiotherapy departments, along with solutions provided using `LQL-equiv` and its developers. The most probable responses from the sample of clinicians present at the conference are also documented. This allows each radiotherapy team to compare its practice with these results, facilitating reflection on clinical decision-making and potential improvements in treatment planning. To move towards standardization, the next step should be the creation of a practical guide on the use of `LQ` and `LQL` models in clinical settings, incorporating best practices derived from this study. Additionally, a working group could be established to foster collaboration between institutions, ensuring a harmonized approach to dose equivalence calculations. Finally, future developments should aim at integrating these models into clinically validated digital tools that facilitate decision-making and minimize subjective interpretation. Given these findings, it is urgent to repeat such workshops to guide practitioners and systematically compare practices. Establishing regular assessments would help pave the way toward the harmonization of equivalent dose calculations in the medium term. It is unacceptable that tumor control and radiation-induced effects depend on the treatment center or the individual performing the calculations, especially when technical capabilities are equivalent. Ensuring consistency in radiotherapy protocols should be a priority to guarantee optimal patient care across different institutions.

Conflicts of interest/Competing interests

The authors declare that they have no conflicts of interest or competing interests related to this work.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Ethics approval

No ethical approval was required for this study, as no patient data was used. The simulations were based solely on fictitious case studies.

Data availability Statement

The data used in this study is available upon reasonable request to the corresponding author, within the limits of feasibility.

References

[1] Melvin Astrahan. Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. *Medical Physics*, 35(9):4161–4172, 2008. doi: https://doi.org/10.1118/1.2969065.

[2] Søren M. Bentzen. Towards evidence-based dose escalation in radiation oncology: Bed and isoeffect relationships for late morbidity and tumor control. *International Journal of Radiation Oncology, Biology, Physics*, 82:1–6, 2012. doi: 10.1016/j.ijrobp.2010.12.007.

[3] Roger G. Dale. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. *British Journal of Radiology*, 62:201–207, 1989. doi: 10.1259/0007-1285-62-735-201.

[4] Thilo Elsässer. Quantification of rbe effects in ion beam therapy based on the local effect model (lem). *Physics in Medicine and Biology*, 55:7241–7257, 2010. doi: 10.1088/0031-9155/55/23/004.

[5] Jack F. Fowler. The linear-quadratic formula and progress in fractionated radiotherapy. *British Journal of Radiology*, 62:679–694, 1989. doi: 10.1259/0007-1285-62-740-679.

[6] International Atomic Energy Agency (IAEA). Radiation protection and safety in medical uses of ionizing radiation, 2018. URL `https://www.iaea.org/publications/12290/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation`. Safety Standards Series No. SSG-46.

[7] D. E. Lea and D. G. Catcheside. The mechanism of the indirect action of radiation. *Nature*, 150:493–494, 1942. doi: 10.1038/150493a0.

[8] J. T. Lyman. Complication probability as assessed from dose-volume histograms. *Radiation Research*, 104:S13–S19, 1985. doi: 10.2307/3576620.

[9] Andrzej Niemierko. A generalized concept of equivalent uniform dose (eud). *Medical Physics*, 27:1101–1106, 2000. doi: 10.1118/1.598935.

[10] Harald Paganetti. *Proton Therapy Physics*. CRC Press, 2019.

[11] Renato Real, Rubens Vargas, and M. Costa. Evaluating consistency in medical datasets: The jaccard similarity index. *Journal of Statistical Computation and Simulation*, 83(4):637–651, 2013. doi: 10.1080/00949655.2011.647745. URL `https://doi.org/10.1080/00949655.2011.647745`.

[12] Howard Thames and Søren M. Bentzen. *Fractionation in Radiotherapy: Mechanisms and Strategies*. Taylor & Francis, 1985.

[13] Cyril Voyant and Daniel Julian. A short synthesis concerning biological effects and equivalent doses in radiotherapy. *Journal of Radiology and Oncology*, 1(1):039–045, Mar 2017. doi: 10.29328/journal.jro.1001005. URL `https://doi.org/10.29328/journal.jro.1001005`.

[14] Cyril Voyant, Daniel Julian, Rudy Roustit, Katia Biffi, and Céline Lantieri. Biological effects and equivalent doses in radiotherapy: A software solution. *Reports of Practical Oncology & Radiotherapy*, 19(1):47–55, 2014. ISSN 1507-1367. doi: https://doi.org/10.1016/j.rpor.2013.08.004. URL `https://www.sciencedirect.com/science/article/pii/S1507136713010249`.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Appendix A. Detailed Clinical Cases

The clinical cases presented in this section illustrate the challenges posed by the radiotherapy management of patients with brain metastases. We will explore the different therapeutic strategies considered and the decision-making criteria that guided the choice of treatment. Figures A1 and A2 provide visual representations of the cases and the proposed solutions.

Appendix B. Algorithm for Jaccard Similarity (J) and Mode Determination

The evaluation of participant responses was guided by two complementary metrics: the Jaccard similarity index and the mode. The Jaccard index quantifies the consistency of responses by calculating the proportion of shared elements between pairs of responses relative to the total. Meanwhile, the mode identifies the most frequent response, shedding light on collective tendencies in decision-making. Algorithm 1 outlines the process for computing both metrics. The Jaccard similarity measures agreement, while the mode highlights the dominant adjustment strategy. Together, they provide a comprehensive picture of participant behavior.

Algorithm 1 Jaccard Similarity and Mode Calculation

```
Require: responses: A vector of numerical responses
Ensure: jaccard: Jaccard similarity index in percentage
Ensure: mode: The most frequent response
  Initialize counters: similarCount = 0, numPairs = 0, responseCounts = {}
  for each unique pair of responses (i, j) do
    if responses[i] == responses[j] then
      Increment similarCount
    end if
    Increment numPairs
  end for
  for each response r in responses do
    Increment responseCounts[r] or initialize it to 1
  end for
  jaccard = (similarCount / numPairs) * 100
  mode = response in responseCounts with maximum count
  Return jaccard, mode
```

The results of these calculations reflect not only the degree of agreement among participants but also the most prevalent adjustment strategy. For example, in the case of interrupted treatments (case 3), the mode revealed that most participants preferred to maintain the duration of treatment while favoring low dose levels per fraction. Such insights are essential for understanding collective decision-making and optimizing future training efforts.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure A1: Clinical cases 1 and 2. The yellow boxes contain proposed solutions for each problem using `LQL-equiv`, formulated by C. Voyant and D. Julian.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.05.25323402; this version posted March 6, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure A2: Clinical cases 3 and 4. The yellow boxes contain proposed solutions for each problem using `LQL-equiv`, formulated by C. Voyant and D. Julian.